TrialPath
Recruiting

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

NCT04752826 · BioInvent International AB
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
Phase 1/2a Open-Label, Dose-Escalation, Multicenter, FIH, Consecutive-Cohort, Clinical Trial of BI-1808, a Monoclonal Antibody to TNFR 2 as a Single Agent and in Combination With Pembrolizumab (MK-3475-D20) in Subjects With Advanced Malignancies
About this study
This is a Phase 1/2a, dose-escalation, multicenter, first-in-human, consecutive-cohort, open-label study of BI-1808, as a single agent, in combination with pembrolizumab, and in BI-1808 in combination with pembrolizumab and paclitaxel in subjects with advanced malignancies, whose disease has progressed after standard therapy. The study will consist of 2 phases: a Phase 1 with Parts A and B, and a Phase 2a with Parts A , B and C. Phase 1 Part A consists of a dose escalation of BI-1808 as a single agent to evaluate safety and tolerability and to determine the RP2D as a single agent (sRP2D) in subjects with advanced malignancies whose disease has progressed after standard therapy. Phase 1 Part B consists of a dose escalation of BI-1808 in combination with pembrolizumab to evaluate the safety and tolerability of the combination treatment and to allow selection of the RP2D for BI-1808 in combination with pembrolizumab (cRP2D) in subjects with advanced malignancies whose disease has progressed after standard therapy. Phase 2a will assess BI-1808 administered as a single agent (Part A), in combination with pembrolizumab (Part B), and in combination with pembrolizumab and paclitaxel (Part C) at the respective hypothesized RP2D(s) determined in Phase 1. Phase 2a expansion will be conducted in indication specific signal seeking cohorts and indication specific Dose Optimization Cohorts) of subjects. The Phase 2a study aims to further evaluate the safety and tolerability of BI-1808 as monotherapy (Part A), in combination with pembrolizumab (Part B), and in combination with pembrolizumab and paclitaxel (Part C). Including characterization of the PK and PD profiles of BI-1808, evaluation of preliminary antitumor activity based on ORR, DoR, and progression-free survival (PFS) as assessed by RECIST v1.1 and iRECIST, and determination of the recommended Phase 2 dose (RP2D).
Eligibility criteria
Inclusion Criteria: * Able and willing to provide written informed consent. * Aged 18 years or older. * Histologically confirmed advanced or metastatic malignancy eligible for an enrolling study cohort. * Disease progression following, intolerance of, ineligibility for, or refusal of applicable standard therapy. * At least one measurable lesion according to the response criteria specified in the protocol. * Eastern Cooperative Oncology Group performance status of 0 or 1. * Life expectancy of at least 12 weeks. * Adequate organ function. * Willing and medically suitable to provide required tumor or skin biopsies. * Meets the disease-specific and treatment-history requirements of the applicable Phase 2a cohort. * For Phase 2a Part C: Histologically confirmed platinum-resistant high-grade serous or clear-cell ovarian carcinoma, prior platinum-based treatment as specified in the protocol, and suitability for paclitaxel treatment. Exclusion Criteria: 1\. Active central nervous system metastases or carcinomatous meningitis. * Active or clinically significant autoimmune disease, immunodeficiency, or use of prohibited immunosuppressive treatment. * Prior treatment-related toxicity not recovered to the level specified in the protocol. * Prior anticancer therapy, radiotherapy, immunotherapy, investigational treatment, or live vaccine within the protocol-defined washout period. * History of clinically significant immune-mediated toxicity, including pneumonitis, associated with previous immune-checkpoint inhibitor treatment. * Uncontrolled or clinically significant cardiovascular disease, serious infection, or another condition that could compromise safety or study participation. * Major surgery without adequate recovery. * Prior allogeneic tissue or solid-organ transplantation or active graft-versus-host disease. * Pregnancy or breastfeeding, or unwillingness to comply with protocol-defined contraceptive requirements. * Known hypersensitivity to a study treatment or its components. * Another active malignancy, except for protocol-defined permitted malignancies. * Participation in another interventional clinical trial that conflicts with this study. * Unable or unlikely to comply with study procedures and requirements. * For Phase 2a Part C: Receipt of prohibited colony-stimulating factors within the protocol-defined period before treatment.
Study design
Enrollment target: 250 participants
Allocation: non_randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2021-01-25
Estimated completion: 2028-12-31
Last updated: 2026-09-18
Interventions
Drug: BI-1808Drug: Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for InjectionDrug: Paclitaxel 80 mg/m2 weekly
Primary outcomes
  • • Occurrence of adverse events (AEs) (From the start of the study treatment for up to 2 years and 90 days.)
  • • Identify DLTs, determine the maximum tolerated dose and select a recommended Phase 2 dose (RP2D) of BI-1808, given via intravenous (IV) infusion, as a single agent (Phase 1, Part A), and in combination with pembrolizumab (Phase 1, Part B) (Up to 104 weeks (2 years))
  • • Occurrence of serious adverse events (SAEs) (Up to 104 weeks (2 years))
Sponsor
BioInvent International AB · industry
With: Merck Sharp & Dohme LLC
Contacts & investigators
ContactSusanne Gertsson · contact · susanne.gertsson@bioinvent.com · +46462868550
ContactMona Welschof, PhD · contact · mona.welschof@bioinvent.com · +47 97088721
InvestigatorAndres McAllister, PhD · study_director, BioInvent International AB
All locations (25)
City of Hope National Medical CenterRecruiting
Duarte, California, United States
Memorial Sloan Kettering Cancer CenterRecruiting
New York, New York, United States
University of PennsylvaniaRecruiting
Philadelphia, Pennsylvania, United States
RigshospitaletRecruiting
Copenhagen, Denmark
Herlev HospitalRecruiting
Herlev, Denmark
PRA Health Sciences - HungaryActive Not Recruiting
Budapest, Hungary
Magyar Honvédség-Egészségügyi KözpontRecruiting
Budapest, Hungary
Debreceni Egyetem Klinikai KözpontWithdrawn
Debrecen, Hungary
Byudzhetnoye Uchrezhdeniye Zdravookhraneniya Omskoy Oblasti - Klinicheskiy Onkologicheskiy DispanserTerminated
Omsk, Russia
National Medical Research Center VA AlmazovWithdrawn
Saint Petersburg, Russia
N.N. Petrov National Medical Research Center of OncologyWithdrawn
Saint Petersburg, Russia
Institut Catala d'oncologia. Hospital Duran I ReynalsNot Yet Recruiting
Barcelona, Spain
Hospital Universitario Puerta de Hierro-Majadahonda, Madrid,Not Yet Recruiting
Madrid, Spain
START Madrid - Hospital Universitario Fundación Jiménez DíazRecruiting
Madrid, Spain
Hospital Universitario 12 de OctubreRecruiting
Madrid, Spain
Sahlgrenska University HospitalRecruiting
Gothenburg, Sweden
Skanes University HospitalRecruiting
Lund, Sweden
Karolinska University Hospital, SolnaRecruiting
Stockholm, Sweden
University Hospital BirminghamRecruiting
Birmingham, United Kingdom
University Hospitals of Leicester NHS TrustRecruiting
Leicester, United Kingdom
Guy's and Saint Thomas' NHS Foundation TrustRecruiting
London, United Kingdom
Sarah Cannon Research Institute UKRecruiting
London, United Kingdom
The Royal Marsden Hospital NHS Foundation TrustRecruiting
London, United Kingdom
The Christie NHS Foundation TrustRecruiting
Manchester, United Kingdom
Southampton General HospitalRecruiting
Southampton, United Kingdom
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20) · TrialPath